

# **BD launches infectious disease molecular Dx platform**

written by CAP TODAY  
May 23, 2022

May 23, 2022—BD announced the U.S. launch of its fully automated, high-throughput infectious disease molecular diagnostics platform, the BD COR MX.



©2026 CAP TODAY, all rights reserved.

---

# **FDA approves Enhertu for breast cancer**

written by CAP TODAY  
May 23, 2022

May 18, 2022—Daiichi Sankyo and AstraZeneca's Enhertu (fam-trastuzumab deruxtecan-nxki) has been approved in the United States for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy.



©2026 CAP TODAY, all rights reserved.

---

# Leaving behind outdated AST breakpoints

written by CAP TODAY

May 23, 2022

May 2022—Among the countless interruptions COVID-19 has inflicted on the medical community, one of the most obvious has been conversational. In the face of a global pandemic, other topics can seem unworthy of discussion. But as some post-pandemic normalcy creeps back in, so does the focus on topics of equal, if less dramatic, importance.



©2026 CAP TODAY, all rights reserved.

---

# On the track of new approaches to myocarditis

written by CAP TODAY

May 23, 2022

May 2022—Studies show promise for new approaches to biomarkers for myocarditis diagnosis, one of which is circulating microRNA mmu-miR-721. Another biomarker, sera soluble ST2 (sST2), which has been found to be clinically useful in predicting heart failure, could be added to existing biomarkers used to diagnose patients with myocarditis, interpreted according to sex and age. And serial high-sensitivity troponin measurements might be another approach to diagnosing and monitoring myocarditis.



©2026 CAP TODAY, all rights reserved.

---

# [Integrating NGS into the cytopenia workup](#)

written by CAP TODAY

May 23, 2022

May 2022—Myelodysplastic syndromes are often challenging to diagnose, and it's the exceptions to the rules that make it so, said Phillipp W. Raess, MD, PhD, associate professor of pathology and laboratory medicine, Oregon Health and Science University, speaking at CAP21.



©2026 CAP TODAY, all rights reserved.

---

# [FDA approves Hologic Aptima CMV Quant assay](#)

written by CAP TODAY

May 23, 2022

May 16, 2022—Hologic announced that the FDA approved its Aptima CMV Quant assay to quantify the viral load of cytomegalovirus in patients who have had solid organ or stem cell transplants.



©2026 CAP TODAY, all rights reserved.

---

# [High hopes for schools as lab positions go](#)

## unfilled

written by CAP TODAY  
May 23, 2022

May 2022—Opening and expanding schools—the path to a labor pool for labs. Compass Group members continue to move on that as they experiment with other solutions. “We’re exploring every avenue to bridge the staffing gap,” said Dhobie Wong of Sutter Health in a virtual roundtable with CAP TODAY publisher Bob McGonnagle on April 5.



©2026 CAP TODAY, all rights reserved.

---

## When surgical pathology is key to infectious disease

written by CAP TODAY  
May 23, 2022

May 2022—Infectious disease diagnosis sometimes requires a surgical pathologist, often in unexpected situations. In a CAP21 session, “Uncultured: Infectious Diseases in Surgical Pathology,” Sarah D. Hackman, MD, assistant professor, Department of Pathology and Laboratory Medicine, University of Texas Health San Antonio, presented a sampling of such cases, two of which follow.



©2026 CAP TODAY, all rights reserved.

---

## [For inspectors, a new and better training course](#)

written by CAP TODAY  
May 23, 2022

May 2022—Users of the CAP’s redesigned laboratory inspector training course, introduced last December, should find it to be more fun, less chore, and tailored to what they need to know, say those who developed the new course. And it’s open and accessible to all.



©2026 CAP TODAY, all rights reserved.

---

## [In next-gen sequencing, aiming for wider access](#)

written by CAP TODAY  
May 23, 2022

May 2022—Next-generation sequencing—the worries, the wins, and what’s new. That’s what came up when CAP TODAY publisher Bob McGonnagle led an NGS-focused roundtable on March 14. With him were Jeremy Segal, MD, PhD, of the University of Chicago; Pierre Del Moral, PhD, MBA, and Fiona Nohilly of Illumina; Sohaib Qureshi, PhD, of Thermo Fisher Scientific; and Andy Johnson, DPhil, of Janssen. Here’s what they had to say.



©2026 CAP TODAY, all rights reserved.